Terlipressin versus other vasoactive drugs for hepatorenal syndrome
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Terlipressin Versus Other Vasoactive Drugs for Hepatorenal Syndrome." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome_New. Accessed 20 April 2024.
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome_New. Accessed April 20, 2024.
Terlipressin versus other vasoactive drugs for hepatorenal syndrome. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome_New
Terlipressin Versus Other Vasoactive Drugs for Hepatorenal Syndrome [Internet]. In: Cochrane Abstracts. [cited 2024 April 20]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Terlipressin versus other vasoactive drugs for hepatorenal syndrome
ID - 438822
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438822/all/Terlipressin_versus_other_vasoactive_drugs_for_hepatorenal_syndrome_New
DB - Evidence Central
DP - Unbound Medicine
ER -